Last reviewed · How we verify
Infliximab, methylprednisolone, methotrexate
This combination suppresses TNF-α signaling and T-cell proliferation to reduce inflammatory immune responses in autoimmune diseases.
This combination suppresses TNF-α signaling and T-cell proliferation to reduce inflammatory immune responses in autoimmune diseases. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | Infliximab, methylprednisolone, methotrexate |
|---|---|
| Sponsor | Université Catholique de Louvain |
| Drug class | TNF-α inhibitor combination therapy |
| Target | TNF-α receptor; dihydrofolate reductase; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Infliximab is a TNF-α inhibitor monoclonal antibody that blocks tumor necrosis factor-alpha, a key inflammatory cytokine. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase and reduces T-cell proliferation. Methylprednisolone is a corticosteroid that broadly suppresses immune activation. Together, these agents provide multi-modal immunosuppression for severe inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
Common side effects
- Infection (including serious/opportunistic)
- Infusion reactions
- Headache
- Nausea
- Immunosuppression-related malignancy risk
- Tuberculosis reactivation
- Hepatotoxicity
- Bone marrow suppression
Key clinical trials
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis (PHASE3)
- A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab (PHASE2)
- Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA) (PHASE4)
- Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World" (PHASE4)
- RETRO (REduction of Therapy in RA Patients in Ongoing Remission) (PHASE3)
- Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (PHASE3)
- TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis (PHASE4)
- Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: